Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease ...

[1] Lichenification may arise from normal-appearing skin ("lichen simplex chronicus") or may be superimposed on some other underlying dermatological disorder such as psoriasis, lichen sclerosus ...

In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, ...

Phase III studies are ongoing on Dupixent for chronic pruritus of unknown origin and lichen simplex chronicus. In 2024, Dupixent generated global product sales of $€13.07 billion ($14.15 billion ...

School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P. R. China Tianjin Key Laboratory of Therapeutic Substance of Traditional Chinese Medicine, ...